Tuhura Biosciences, Inc. (HURA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on November 18, 2025, by Tuhura Biosciences, Inc., a Nevada corporation. The filing addresses Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). The report focuses on the provision of unaudited pro forma financial statements following the company's acquisition of Kineta, Inc., which was completed on June 30, 2025.
Key Financial Metrics
The filing does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Instead, it serves as a cover document incorporating by reference the "Unaudited Pro Forma Condensed Combined Statements of Operations" attached as Exhibit 99.1. These pro forma statements cover:
- The nine months ended September 30, 2025.
- The year ended December 31, 2024.
The pro forma data assumes the Mergers with Kineta and the prior reverse merger with Kintara Therapeutics, Inc. (closed October 18, 2024) were consummated on January 1, 2024.
Material Changes
The primary material event disclosed is the completion of the acquisition of Kineta, Inc. on June 30, 2025, pursuant to the Merger Agreement dated December 11, 2024, as amended. The transaction involved a two-step merger process where Kineta merged into a subsidiary of Tuhura, and the surviving entity subsequently merged into a second Tuhura subsidiary. This filing updates the financial picture to reflect the combined entity's operations on a pro forma basis.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statements cautioning that actual results may differ materially from expectations due to various risks and uncertainties. It references the "Risk Factors" section of the company's Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q for a detailed list of potential risks. The company explicitly states it undertakes no obligation to update forward-looking statements except as required by law. No specific financial guidance or management commentary regarding future performance metrics is provided in this text.
Investor Verification Checklist
- Exhibit 99.1: Review the attached Unaudited Pro Forma Condensed Combined Statements of Operations for specific revenue and loss figures for the periods ended September 30, 2025, and December 31, 2024.
- Merger Terms: Verify the final terms of the Kineta acquisition and the impact on share count and capitalization.
- Risk Factors: Consult the most recent Form 10-K and 10-Q filings for updated risk disclosures relevant to the combined entity.
- Pro Forma Adjustments: Examine the notes to the pro forma financial statements to understand the specific accounting adjustments made to simulate the mergers as of January 1, 2024.